| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BIRC7 |
| Uniprot No | Q96CA5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-298aa |
| 氨基酸序列 | MGPKDSAKCL HRGPQPSHWA AGDGPTQERC GPRSLGSPVL GLDTCRAWDH VDGQILGQLR PLTEEEEEEG AGATLSRGPA FPGMGSEELR LASFYDWPLT AEVPPELLAA AGFFHTGHQD KVRCFFCYGG LQSWKRGDDP WTEHAKWFPS CQFLLRSKGR DFVHSVQETH SQLLGSWDPW EEPEDAAPVA PSVPASGYPE LPTPRREVQS ESAQEPGGVS PAEAQRAWWV LEPPGARDVE AQLRRLQEER TCKVCLDRAV SIVFVPCGHL VCAECAPGLQ LCPICRAPVR SRVRTFLS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BIRC7重组蛋白的3篇参考文献示例(注：内容为模拟概括，实际文献需根据具体数据库检索)：
---
1. **《重组人BIRC7蛋白的制备及其在肝癌细胞凋亡中的作用研究》**
- 作者：李明等
- 摘要：本研究通过基因克隆技术在大肠杆菌中表达并纯化了BIRC7重组蛋白，发现其能显著抑制肝癌细胞凋亡，并证实其作用与 caspase-3/7 通路抑制相关，为靶向治疗提供了实验依据。
2. **《BIRC7重组蛋白增强黑色素瘤化疗耐药性的机制分析》**
- 作者：Smith J, et al.
- 摘要：利用重组BIRC7蛋白处理黑色素瘤细胞，发现其通过上调XIAP和 Survivin 表达，降低顺铂诱导的细胞凋亡率，提示BIRC7可能是逆转耐药性的潜在靶点。
3. **《Structural insights into BIRC7 recombinant protein and its interaction with Smac/DIABLO》**
- 作者：Wagner A, et al.
- 摘要：通过X射线晶体学解析了BIRC7重组蛋白的三维结构，揭示了其BIR结构域与 Smac 蛋白的结合位点，为设计小分子抑制剂提供了结构基础。
---
如需实际文献，建议在 **PubMed** 或 **Web of Science** 中检索关键词“BIRC7 recombinant protein”、“livin recombinant”等。
BIRC7. also known as survivin, is a member of the inhibitor of apoptosis (IAP) protein family, characterized by its dual role in regulating cell survival and division. Encoded by the BIRC7 gene, this 16.5 kDa protein contains a single baculovirus IAP repeat (BIR) domain critical for its anti-apoptotic function and a coiled-coil domain that facilitates protein-protein interactions. Unlike other IAPs, survivin is uniquely involved in both apoptosis inhibition and mitotic progression, primarily through binding to chromosomal passenger complex (CPC) components during cell division.
Originally identified for its overexpression in cancer cells, survivin is virtually undetectable in most differentiated tissues but becomes markedly upregulated in various malignancies, including breast, lung, and colorectal cancers. Its oncogenic potential stems from two mechanisms: suppression of caspase-mediated apoptosis through direct interaction with executioner caspases, and regulation of microtubule dynamics during mitosis to ensure proper chromosomal segregation. Additionally, survivin participates in angiogenesis by stabilizing hypoxia-inducible factors in tumor microenvironments.
Recombinant BIRC7 protein is typically produced in bacterial or eukaryotic expression systems for research and therapeutic development. Its purified form enables structural studies, inhibitor screening, and functional assays investigating cancer biology. In drug discovery, survivin-targeting strategies using recombinant protein include designing small-molecule inhibitors, antisense oligonucleotides, and immunotherapies like survivin-directed vaccines. Recent studies also explore its potential as a prognostic biomarker in liquid biopsies.
Despite promising applications, challenges persist in targeting survivin due to its complex cellular localization and dual functionality. Current research focuses on isoform-specific regulation and combination therapies to overcome treatment resistance. The protein's cancer-specific expression profile continues to make it a compelling target for precision oncology approaches.
×
